← All Precigen, INC filings

Precigen, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
PGEN
Precigen, INC
10-K: Precigen Secures Full FDA Approval for Papzimeos, Shifts Focus to Commercialization
Precigen achieved a significant milestone with full FDA approval for Papzimeos, its first commercial product for recurrent respiratory papillomatosis, as it navigates substantial financial losses and strategic pipeline adjustments.
NASDAQ
PGEN
Precigen, INC
10-K/A: Precigen Files Amendment No. 1 to Form 10-K/A for Fiscal Year 2024, Including Part III Information
Precigen files an amendment to its 2024 annual report to include information previously omitted from Part III, covering directors, executive officers, compensation, and corporate governance.
NASDAQ
PGEN
Precigen, INC
10-K: Precigen's 2024 10-K Filing: Strategic Shift to PRGN-2012 and Financial Outlook
Precigen's 2024 10-K filing highlights a strategic shift towards PRGN-2012, financial uncertainties, and ongoing research and development efforts.
NASDAQ
PGEN
Precigen, INC
10-K/A: Precigen Files Amended 10-K to Include Omitted Part III Information
Precigen, Inc. has filed an amendment to its annual report on Form 10-K to include information previously omitted from Part III, related to directors, executive officers, and corporate governance.
NASDAQ
PGEN
Precigen, INC
10-K: Precigen's 2023 Annual Report: Focus on Gene and Cell Therapies Amidst Financial Challenges
Precigen's 2023 annual report highlights its advancements in gene and cell therapies while acknowledging substantial doubt about its ability to continue as a going concern due to ongoing losses.